Malvern Instrument?s Announces Guest Presenter for March 18th Protein Characterisation Webinar
Malvern Instruments welcomes Prof. Dr. John F. Carpenter, from the University of Colorado Center for Pharmaceutical Biotechnology, as a guest presenter contributing to the company’s current series of webinars.
Professor Carpenter is a renowned expert in mechanisms for protein degradation and stabilization in pharmaceutical formulations. In his webinar on 18 March 2014 he will discuss how the combination of dynamic light scattering technology with Raman spectroscopy delivers new insights into the measurement and prediction of protein stability, aggregation and high order structure.
The non-invasive and non-destructive determination of numerous physicochemical properties of protein therapeutics and their aggregates is critical for developing formulation conditions that enhance product efficacy, stability and manufacturability. To meet the analytical challenges in early stage development, where the amount of material is limited, tools that measure very small volumes are also highly desirable.
In his webinar presentation, Prof. Carpenter will describe the combination of two established analytical techniques, dynamic light scattering (DLS) and Raman spectroscopy. Together they can be used to derive structural, thermodynamic and kinetic insights into the mechanisms of protein aggregation and the factors that influence protein stability. He will present a number of examples using model systems and manufactured biopharmaceutical products to illustrate the synergies of the two techniques and the new insights afforded by the combined approach.
Looking forward to the webinar, Dr Lisa Newey-Keane, Biopharmaceutical Portfolio Manager for Malvern, said: “We are delighted that Prof. Carpenter has agreed to talk about the work that he has been doing and to describe the use of a combined DLS/Raman Spectroscopy approach to protein characterization. His expertise in protein systems, especially in biopharmaceutical formulations, will provide a highly informative backdrop to the combined application of these two techniques and the examples he plans to describe will put this into the context of solving real-world problems.”
Prof. Dr John F. Carpenter is an expert in mechanisms for protein degradation and stabilization in pharmaceutical formulations, during bioprocessing and in delivery systems. He has published more than 200 peer-reviewed papers and is an inventor on 19 issued patents. He is Editor for Reviews and Commentaries for Journal of Pharmaceutical Sciences and serves on the Editorial Advisory Boards for various pharmaceutical journals.
Webinar registration is free and is open to all as part of Malvern’s continuing programme of information and education. For further details and to register, please visit www.malvern.com/dlsraman
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...